Loading...
FLRY3 logo

Fleury S.A.BOVESPA:FLRY3 Stock Report

Market Cap R$8.7b
Share Price
R$16.00
My Fair Value
R$15.97
0.2% overvalued intrinsic discount
1Y5.6%
7D-0.6%
Portfolio Value
​
View

Fleury S.A.

BOVESPA:FLRY3 Stock Report

Market Cap: R$8.7b

Fleury (FLRY3) Stock Overview

Provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. More details

FLRY3 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Rewards

Trading at 21.7% below our estimate of its fair value

Earnings have grown 19.8% per year over the past 5 years

Risk Analysis

Unstable dividend track record


FLRY3 Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

FLRY3 logo
Fleury

Digital Investments And Demographics Will Transform Diagnostic Medicine

Key Takeaways Digital innovation, service expansion, and automation are strengthening operational efficiency, profitability, and market reach while supporting sustainable earnings growth. Demographic trends and geographic expansion are creating resilient demand, diversifying revenue streams, and reinforcing volume-driven top-line growth.
View narrative
R$15.97
FV
0.2% overvalued intrinsic discount
6.20%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
11 days ago author updated this narrative
FLRY3 logo
Fleury

Aging Population And AI Will Redefine Preventive Healthcare

Key Takeaways Integration of acquisitions and advanced technology adoption position Fleury for significant scalability, margin expansion, and superior returns relative to expectations. Premium market presence, digital transformation, and asset-light expansion strategies drive accelerated growth and strengthen long-term market leadership potential.
View narrative
R$19.5
FV
17.9% undervalued intrinsic discount
7.68%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
23 days ago author updated this narrative
FLRY3 logo
Fleury

Rising Inequality In Brazil And Digital Disruption Will Compress Margins

Key Takeaways Rising inequality, government cost controls, and increased competition threaten future demand, pricing power, and profitability for Fleury in Brazil's private healthcare sector. Rapid digital disruption and reliance on acquisitions risk eroding Fleury's market differentiation, pressuring margins and hampering long-term integration and earnings growth.
View narrative
R$12.5
FV
28.0% overvalued intrinsic discount
6.10%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 1 month ago author updated this narrative
View Stock Community

Fleury S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Fleury
Historical stock prices
Current Share PriceR$16.00
52 Week HighR$16.35
52 Week LowR$10.65
Beta0.33
1 Month Change3.69%
3 Month Change22.89%
1 Year Change5.61%
3 Year Change-14.11%
5 Year Change-39.39%
Change since IPO84.11%

Recent News & Updates

Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Sep 24
Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking

Jun 19
Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking

Recent updates

Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Sep 24
Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking

Jun 19
Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking

Fleury's (BVMF:FLRY3) Solid Earnings Are Supported By Other Strong Factors

May 17
Fleury's (BVMF:FLRY3) Solid Earnings Are Supported By Other Strong Factors

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Apr 15
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Analysts Have Been Trimming Their Fleury S.A. (BVMF:FLRY3) Price Target After Its Latest Report

Mar 02
Analysts Have Been Trimming Their Fleury S.A. (BVMF:FLRY3) Price Target After Its Latest Report
User avatar

Digital Transformation And Pardini Integration Will Improve Efficiency And Capture Niche Markets

Expansion into specialized integrated centers and mobile services could drive revenue growth and improve margins without substantial capital expenditure.

Fleury's (BVMF:FLRY3) Dividend Is Being Reduced To R$0.2139

Dec 15
Fleury's (BVMF:FLRY3) Dividend Is Being Reduced To R$0.2139

We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve

Nov 15
We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve

Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly

Nov 02
Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly

Fleury S.A.'s (BVMF:FLRY3) Price Is Out Of Tune With Earnings

Sep 26
Fleury S.A.'s (BVMF:FLRY3) Price Is Out Of Tune With Earnings

We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt

Jun 18
We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt

The Price Is Right For Fleury S.A. (BVMF:FLRY3)

Apr 16
The Price Is Right For Fleury S.A. (BVMF:FLRY3)

Concerns Surrounding Fleury's (BVMF:FLRY3) Performance

Mar 14
Concerns Surrounding Fleury's (BVMF:FLRY3) Performance

Earnings Tell The Story For Fleury S.A. (BVMF:FLRY3)

Jan 05
Earnings Tell The Story For Fleury S.A. (BVMF:FLRY3)

Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Oct 05
Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Jun 27
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt

Feb 25
We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt

At R$18.27, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Sep 26
At R$18.27, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Sep 08
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Fleury (BVMF:FLRY3) Has Some Way To Go To Become A Multi-Bagger

Jul 01
Fleury (BVMF:FLRY3) Has Some Way To Go To Become A Multi-Bagger

When Should You Buy Fleury S.A. (BVMF:FLRY3)?

Jun 10
When Should You Buy Fleury S.A. (BVMF:FLRY3)?

Is Fleury (BVMF:FLRY3) Using Too Much Debt?

Apr 10
Is Fleury (BVMF:FLRY3) Using Too Much Debt?

Return Trends At Fleury (BVMF:FLRY3) Aren't Appealing

Mar 24
Return Trends At Fleury (BVMF:FLRY3) Aren't Appealing

At R$19.12, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Feb 08
At R$19.12, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Returns On Capital Are Showing Encouraging Signs At Fleury (BVMF:FLRY3)

Dec 08
Returns On Capital Are Showing Encouraging Signs At Fleury (BVMF:FLRY3)

Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly

Nov 05
Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly

Is Fleury S.A. (BVMF:FLRY3) Potentially Undervalued?

Oct 21
Is Fleury S.A. (BVMF:FLRY3) Potentially Undervalued?

Investors Should Be Encouraged By Fleury's (BVMF:FLRY3) Returns On Capital

Aug 24
Investors Should Be Encouraged By Fleury's (BVMF:FLRY3) Returns On Capital

Fleury (BVMF:FLRY3) Seems To Use Debt Rather Sparingly

Jul 31
Fleury (BVMF:FLRY3) Seems To Use Debt Rather Sparingly

Is It Time To Consider Buying Fleury S.A. (BVMF:FLRY3)?

Jul 07
Is It Time To Consider Buying Fleury S.A. (BVMF:FLRY3)?

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Apr 30
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Fleury (BVMF:FLRY3) Shareholders Will Want The ROCE Trajectory To Continue

Apr 12
Fleury (BVMF:FLRY3) Shareholders Will Want The ROCE Trajectory To Continue

At R$25.16, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Mar 29
At R$25.16, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Should You Or Shouldn't You: A Dividend Analysis on Fleury S.A. (BVMF:FLRY3)

Mar 16
Should You Or Shouldn't You: A Dividend Analysis on Fleury S.A. (BVMF:FLRY3)

Shareholder Returns

FLRY3BR HealthcareBR Market
7D-0.6%0.6%-1.5%
1Y5.6%7.9%0.2%

Return vs Industry: FLRY3 underperformed the BR Healthcare industry which returned 7.6% over the past year.

Return vs Market: FLRY3 exceeded the BR Market which returned 0% over the past year.

Price Volatility

Is FLRY3's price volatile compared to industry and market?
FLRY3 volatility
FLRY3 Average Weekly Movement4.9%
Healthcare Industry Average Movement6.1%
Market Average Movement4.2%
10% most volatile stocks in BR Market8.4%
10% least volatile stocks in BR Market2.0%

Stable Share Price: FLRY3 has not had significant price volatility in the past 3 months compared to the BR market.

Volatility Over Time: FLRY3's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192627,000Jeane Tsutsuiri.fleury.com.br

Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and clinical research in oncology; integrated solutions, research, development of processes and services in genomics; and laboratory analysis services.

Fleury S.A. Fundamentals Summary

How do Fleury's earnings and revenue compare to its market cap?
FLRY3 fundamental statistics
Market capR$8.72b
Earnings (TTM)R$606.21m
Revenue (TTM)R$7.84b
14.4x
P/E Ratio
1.1x
P/S Ratio

Is FLRY3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FLRY3 income statement (TTM)
RevenueR$7.84b
Cost of RevenueR$5.73b
Gross ProfitR$2.11b
Other ExpensesR$1.50b
EarningsR$606.21m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Nov 06, 2025

Earnings per share (EPS)1.11
Gross Margin26.92%
Net Profit Margin7.73%
Debt/Equity Ratio75.4%

How did FLRY3 perform over the long term?

See historical performance and comparison

Dividends

6.4%
Current Dividend Yield
61%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/04 01:18
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fleury S.A. is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Flavio YoshidaBofA Global Research
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários
Carlos Palhares SequeiraBTG Pactual